“There's 3 different levels of dosing…so this does provide you with a mechanism for titration if you're going to be using that in your patients,” says Jesse N. Mills, MD.
In this video, Jesse N. Mills, MD, discusses the important findings from the study, “Subcutaneous Testosterone Enanthate and the Effect of Body Mass Index on Serum Testosterone in Men with Testosterone Deficiency,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Mills is an associate clinical professor of urology at the David Geffen School of Medicine, the director of the UCLA division of Andrology, the director of the Men’s Clinic and the chief of UCLA Santa Monica Urology, University of California, Los Angeles
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.